期刊
CANCERS
卷 13, 期 4, 页码 -出版社
MDPI
DOI: 10.3390/cancers13040840
关键词
chimeric antigen receptor (CAR)-T cell therapy; lymphocytes; immunotherapy; ovarian cancer; endometrial cancer; cervical cancer
类别
This review discusses the current state of research in the field of immunotherapy for gynecological cancers, with a focus on CAR-T cell therapy development. Gynecological tumors have high incidence and mortality rates, with limited efficacy of conventional chemotherapy, but immunotherapy and CAR technology offer new treatment possibilities for these cancer types.
Simple Summary Gynecological cancers represent a group of malignancies with high incidence and mortality, despite their relative sensitivity to platinum-based chemotherapy. This review aims to illustrate the state of research in the field of immunotherapy, and in particular, deals with the development of CAR-T cell therapy, which represents a very promising treatment in the hematological field, but is still taking its first tentative steps in solid tumors. Gynecological tumors are malignancies with both high morbidity and mortality. To date, only a few chemotherapeutic agents have shown efficacy against these cancer types (only ovarian cancer responds to several agents, especially platinum-based combinations). Within this context, the discovery of immune checkpoint inhibitors has led to numerous clinical studies being carried out that have also demonstrated their activity in these cancer types. More recently, following the development of chimeric antigen receptor (CAR)-T cell therapy in hematological malignancies, this strategy was also tested in solid tumors, including gynecological cancers. In this article, we focus on the molecular basis of gynecological tumors that makes them potential candidates for immunotherapy. We also provide an overview of the main immunotherapy studies divided by tumor type and report on CAR technology and the studies currently underway in the area of gynecological malignancies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据